These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23034018)

  • 21. The "Temporary Recommendations for Use": A dual-purpose regulatory framework for off-label drug use in France.
    Degrassat-Théas A; Bocquet F; Sinègre M; Peigné J; Paubel P
    Health Policy; 2015 Nov; 119(11):1399-405. PubMed ID: 26455642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Medical prescriptions to premature and newborn infants in an Austrian neonatal intensive care unit].
    Prandstetter C; Tamesberger M; Wagner O; Weissensteiner M; Wiesinger-Eidenberger G; Weidinger I; Lechner E
    Klin Padiatr; 2009 Sep; 221(5):312-7. PubMed ID: 19707996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Off-label or off-limits?
    Ratner M; Gura T
    Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
    [No Abstract]   [Full Text] [Related]  

  • 24. Health care policy. Reforming off-label promotion to enhance orphan disease treatment.
    Liang BA; Mackey T
    Science; 2010 Jan; 327(5963):273-4. PubMed ID: 20075234
    [No Abstract]   [Full Text] [Related]  

  • 25. The use of Food and Drug Administration--approved medications for unlabeled (off-label) uses. The legal and ethical implications.
    Torres A
    Arch Dermatol; 1994 Jan; 130(1):32-6. PubMed ID: 8285737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Similar concerns. Safety, costs among the issues to be weighed as FDA grapples with crafting an approval process for generic versions of biological medicines.
    Daly R
    Mod Healthc; 2011 Jul; 41(28):38-40. PubMed ID: 21853593
    [No Abstract]   [Full Text] [Related]  

  • 27. Safe drugs and the cost of good intentions.
    Eichler HG; Abadie E; Raine JM; Salmonson T
    N Engl J Med; 2009 Apr; 360(14):1378-80. PubMed ID: 19339718
    [No Abstract]   [Full Text] [Related]  

  • 28. France's blood scandal draws blood.
    Nature; 1992 Oct; 359(6398):759. PubMed ID: 1436041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Easing France's abortion laws.
    Cue E
    Christ Sci Monitor (East Ed); 2000 Aug; 92(178):6-7. PubMed ID: 15586929
    [No Abstract]   [Full Text] [Related]  

  • 30. [How is the RS-virus prophylaxis in Germany adopted?].
    Forster J; Urbanek R
    Klin Padiatr; 2011 Sep; 223(5):257-8. PubMed ID: 21913141
    [No Abstract]   [Full Text] [Related]  

  • 31. Prescrire's proposals to France's national conference on medicines policy: patients' interests and public health should come first.
    Prescrire Int; 2011 May; 20(116):136-8. PubMed ID: 21648182
    [No Abstract]   [Full Text] [Related]  

  • 32. No need for more regulation: payors and their role in balancing the cost and safety considerations of off-label prescriptions.
    Todd AE
    Am J Law Med; 2011; 37(2-3):422-43. PubMed ID: 21847887
    [No Abstract]   [Full Text] [Related]  

  • 33. Speaking off label.
    Latham SR
    Hastings Cent Rep; 2010; 40(6):9-10. PubMed ID: 21140739
    [No Abstract]   [Full Text] [Related]  

  • 34. Off-label drug use as a consent and health regulation issue in New Zealand.
    Cook RJ
    J Bioeth Inq; 2015 Jun; 12(2):251-8. PubMed ID: 25096169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paediatric Oncology at the Crossroads: A Call for Change.
    Rose K
    Pharmaceut Med; 2020 Oct; 34(5):297-300. PubMed ID: 33026589
    [No Abstract]   [Full Text] [Related]  

  • 36. Monitoring the safety of medicines used off-label.
    Dal Pan GJ
    Clin Pharmacol Ther; 2012 May; 91(5):787-95. PubMed ID: 22472983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prescrire: France's Choosing Wisely initiative.
    Toussaint B
    BMJ; 2015 Jun; 350():h3325. PubMed ID: 26108217
    [No Abstract]   [Full Text] [Related]  

  • 38. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
    Mello MM; Studdert DM; Brennan TA
    N Engl J Med; 2009 Apr; 360(15):1557-66. PubMed ID: 19357413
    [No Abstract]   [Full Text] [Related]  

  • 39. Regulating nanomedicine.
    Nat Mater; 2007 Apr; 6(4):249. PubMed ID: 17401411
    [No Abstract]   [Full Text] [Related]  

  • 40. Development of paediatric medicines: concepts and principles.
    Rose K; Della Pasqua O
    Handb Exp Pharmacol; 2011; 205():111-24. PubMed ID: 21882108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.